Trius Therapeutics — Corporate Update (January 2012)
13 slides from Trius Therapeutics's corporate update, Jan 3, 2012
Slide 1: Tedizolid 112 Trial: Top Line Results Update
Exhibit 99.1 Best-in-Class Anti-Infectives Tedizolid 112 Trial: Top Line Results Update January 3, 2012 1
Slide 2: Forward Looking Statements
Forward Looking Statements Statements made in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results
Slide 3: Progression of ABSSSI Regulatory Environment for Phase 3 Studies 112 and 113
Progression of ABSSSI Regulatory Environment for Phase 3 Studies 112 and 113 May 2010: First in a series of FDA requested meetings of the FNIH (Foundation for the National Institutes of Health) working group established to provide recommendations to the FDAon endpoints for clinical trials of drugs f
Slide 4: Tedizolid Phosphate Phase 3 Study Design: Oral (112) and IV/Oral (113) Trials Under SPA
Tedizolid Phosphate Phase 3 Study Design: Oral (112) and IV/Oral (113) Trials Under SPA FDA and EMAEndpoints for Global Registration Safety Analyses Patient Screening 6-Days Tedizolid QD 4-Days Placebo Post Treatment 667 Evaluations Randomization 10-Days Linezolid BID Baseline FDA EMA EMA FDA Primar
Slide 5: Study 112 Primary & Secondary Endpoints: Capturing FDA and EMA Endpoints
Study 112 Primary & Secondary Endpoints: Capturing FDA and EMA Endpoints Primary Endpoint*: Cessation of lesion spread & resolution of fever at 48-72 hour visit after initiation of study drug (ITT analysis set) [FDA Primary Endpoint] Secondary Endpoints: Sustained clinical response at EOT in the ITT
Slide 6: Primary Outcome: All Current and Contemplated Trial 112 Primary Endpoints Achieved
Primary Outcome: All Current and Contemplated Trial 112 Primary Endpoints Achieved in Pre-Specified Analyses Primary Outcome at 48-72 hour visit Treatment Tedizolid Linezolid Lesion Criteria Fever Criteria (200 mg (600 mg QD 6 days) BID 10 days) No increase in lesion area from Temperature measuremen
Slide 7: Secondary Outcomes: Tedizolid Demonstrates Comparable Efficacy with Shorter Course of Therapy
Secondary Outcomes: Tedizolid Demonstrates Comparable Efficacy with Shorter Course of Therapy Secondary Outcome at EOT or PTE Treatment Tedizolid Linezolid Secondary Outcome Criteria (200 mg QD 6 days) (600 mg BID 10 days) Early clinical failures carried 69.3% (ITT) 71.9% (ITT) Clinical Response at
Slide 8: EMA Endpoint: Once-Daily 200mg Tedizolid for 6 Days Demonstrates Comparable Efficacy
EMA Endpoint: A Once-Daily 200mg Dose of Tedizolid for 6 Days Demonstrates Comparable Efficacy to Twice-Daily 600mg Dose of Linezolid for 10 Days of Treatment Secondary Outcome at PTE Treatment Tedizolid Linezolid Secondary Outcome Criteria (200 mg QD 6 days) (600 mg BID 10 days) Clinician assessmen
Slide 9: Shorter Course of Tedizolid Therapy Shows Comparable Per Pathogen Clinical Response
Shorter Course of Tedizolid Therapy Shows Comparable Per Pathogen Clinical Response Clinical investigator’s assessment of clinical response at Post Treatment Evaluation (days 17-24) in the Microbiological Evaluable analysis set Tedizolid Linezolid Pathogen (200mg QD 6 days) (600mg BID 10 days) Staph
Slide 10: Tedizolid was Well Tolerated with a Favorable AE Profile Compared to Linezolid
Tedizolid was Well Tolerated with a Favorable AE Profile Compared to Linezolid Tedizolid had a numerically lower rate of drug-related treatment emergent adverse events (TEAE) and a statistically significant lower number of gastrointestinal adverse events Tedizolid Linezolid Adverse Event (200mg QD 6
Slide 11: Hematology: Tedizolid had Significantly Lower Impact on Platelets than Linezolid
Hematology: Tedizolid had Significantly Lower Impact on Platelets than Linezolid Percent of Patients with Value below the Lower Limit of Normal (LLN) Tedizolid Linezolid Hematology Parameter (200mg QD 6 days) (600mg BID 10 days) Platelets* Below LLN 9.2% 14.9% Platelets - Substantially abnormal valu
Slide 12: Summary
Summary Phase 3 trials conducted under new FDA ABSSSI guidance are manageable Study 112 design and outcomes will satisfy both FDA and EMA regulatory requirements All efficacy and safety objectives of Study 112 were successfully achieved – Efficacy: All primary and secondary trial endpoints met with
Slide 13: Upcoming Milestones
Upcoming Milestones Top line data from 112 Phase 3 ABSSSI trial SPA for and initiation of Phase 3 pneumonia study Potential partner for Europe Initiation of clinical studies for Gyrase Completion of enrollment for 113 Phase 3 ABSSSI trial 13